Skip to main content
. 2022 Mar 23;2(3):158–171. doi: 10.1158/2767-9764.CRC-21-0157

FIGURE 2.

FIGURE 2

HD-derived anti-BCMA CAR T cells have a higher proportion of central memory CD8 T cells compared with multiple myeloma–derived anti-BCMA CAR T cells. A, Schematic diagram of the anti-BCMA CAR construct used, which includes an anti-BCMA scFv, a rituximab-based off-switch, CD8-based hinge and transmembrane region, 4–1BB co-stimulatory domain and CD3z intracellular signaling domain. B, Representative dot plots depicting anti-BCMA CAR expression on live CD3+ T cells by FACS after 14 days of anti-BCMA CAR T-cell production. UT cells were generated from the same donor. C, Percentage of anti-BCMA CAR+ T cells at the end of production generated from HD (n = 7), ND MM (n = 2), early rMM (n = 4), and late rMM patients (n = 4). D, Expression of anti-BCMA CAR (MFI) on CAR T cells generated as above. E, CD4/CD8 ratio of anti-BCMA CAR T cells generated as above. Memory phenotype of CD4 (F) and CD8 (G) anti-BCMA CAR T cells produced from HD (n = 3), newly diagnosed multiple myeloma (ND MM) (n = 2), and relapsed multiple myeloma (rMM) patients (n = 4, including early and late rMM patients). Data represent mean values ± SEM. *P < 0.05; NS, not statistically significant. Statistical analysis was performed using two-tailed unpaired t test.